Rockwell Medical (RMTI) versus Its Rivals Head-To-Head Review
Rockwell Medical (NASDAQ: RMTI) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Rockwell Medical to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, profitability, dividends and institutional ownership.
Volatility & Risk
Rockwell Medical has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Rockwell Medical’s competitors have a beta of 0.81, indicating that their average stock price is 19% less volatile than the S&P 500.
Earnings and Valuation
This table compares Rockwell Medical and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Rockwell Medical||$54.04 million||-$21.07 million||-15.79|
|Rockwell Medical Competitors||$2.40 billion||$905.93 million||3.58|
Rockwell Medical’s competitors have higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Rockwell Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rockwell Medical Competitors||-538.85%||-41.85%||-24.81%|
Insider and Institutional Ownership
21.4% of Rockwell Medical shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 15.9% of Rockwell Medical shares are held by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for Rockwell Medical and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rockwell Medical Competitors||98||367||965||28||2.63|
Rockwell Medical currently has a consensus target price of $9.33, indicating a potential upside of 40.77%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 25.05%. Given Rockwell Medical’s stronger consensus rating and higher possible upside, equities analysts clearly believe Rockwell Medical is more favorable than its competitors.
About Rockwell Medical
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.